Biology and Subtypes: How STAR Deficiency Works
At a Glance
STAR deficiency prevents cholesterol from reaching the cell structures where adrenal and sex hormones are made. This can cause classic or non-classic lipoid congenital adrenal hyperplasia, affecting adrenal function, sex development, and puberty in ways that vary by child.
Understanding the biology of Lipoid Congenital Adrenal Hyperplasia (LCAH) requires looking at how a single protein—the StAR protein—acts as a gatekeeper for the body’s hormone production [1]. When this protein is missing or broken, it sets off a biological chain reaction that affects both adrenal health and physical development [2].
The StAR Protein: A Molecular Shuttle
Inside your child’s cells are tiny power plants called mitochondria. These mitochondria also serve as the factory where the body turns cholesterol into essential hormones like cortisol (for stress and energy) and aldosterone (for salt balance) [3][2].
Cholesterol cannot enter these “factories” on its own. It requires a shuttle called the Steroidogenic Acute Regulatory protein, or StAR [4]. In a person with STAR deficiency, this shuttle is either absent or doesn’t function correctly [1]. Without StAR, the “raw materials” (cholesterol) stay stuck outside the factory, and the body struggles to produce the hormones it needs to survive and grow [2].
The Two-Hit Hypothesis (A Disease Model)
Doctors use a model called the “two-hit hypothesis” to help explain why the adrenal glands and gonads (testes or ovaries) can become damaged over time in this condition [5].
- The First Hit: The initial genetic variation means the StAR protein doesn’t work effectively. This causes a drop in hormone production because cholesterol cannot adequately get into the mitochondria [6].
- The Second Hit: Because the body detects low hormone levels, it sends out “emergency signals” (such as ACTH) to the adrenal glands, telling them to work harder [6]. This causes even more cholesterol to be delivered to the cells. Since it still can’t easily get into the factory, the cholesterol builds up as fat droplets (lipids) inside the cells [7][2]. This buildup can eventually become toxic, causing cellular injury; however, the degree and reversibility of this injury vary widely from person to person [2].
Classic vs. Non-classic LCAH
The severity of the condition depends on how much functional StAR protein remains, though genotype-phenotype correlation is imperfect.
- Classic LCAH: This is the most severe form, involving a severe or total impairment of the StAR protein [8]. It typically presents in the first few months of life with severe salt wasting and adrenal crisis [9].
- Non-classic LCAH: In this form, the protein retains some partial function, allowing for residual steroidogenesis [2]. These children may be diagnosed much later (sometimes in early childhood) and may have milder symptoms initially, though they still face the long-term risk of adrenal insufficiency [10][11].
Karyotypes and Physical Development
Because the StAR protein is also needed to make sex hormones (like testosterone), STAR deficiency affects physical development before a baby is even born. This is often referred to as a Difference of Sex Development (DSD) [12]. The impact depends on the child’s karyotype—their internal chromosomal pattern (46,XX or 46,XY). It is important to note that a chromosomal pattern alone does not determine a person’s gender identity or appropriate individual care plan.
- 46,XX Individuals: Because female anatomical development does not require high levels of prenatal hormones, these infants usually have a typical female external genital appearance at birth [9][2].
- 46,XY Individuals: Fetal development of typical male external genitalia requires a surge of testosterone. In Classic LCAH, the testes may be unable to produce this surge, so the infant is typically born with female external genitalia despite having XY chromosomes and internal testes [2][13].
In Non-classic 46,XY cases, some testosterone may be produced, meaning the infant may have typical male genitalia or varying degrees of masculinization (such as hypospadias) [14][15].
Puberty and Future Growth
The impact on sex development continues into puberty.
- 46,XY Individuals: Depending on gonadal function and gonad management, some with classic disease may require hormone replacement therapy (HRT) for puberty, while non-classic individuals may experience natural puberty [16].
- 46,XX Individuals: These individuals may start puberty naturally (breast development and menstruation) because ovarian function can be variable. However, because the ovaries may also experience “lipid buildup,” they face an individualized risk for premature ovarian insufficiency or ovarian cysts [17][18][19].
Every child is unique, and your medical team will use genetic testing and imaging to understand your child’s specific anatomy and needs, ensuring privacy and consent in DSD discussions.
Common questions in this guide
What does the StAR protein do in lipoid congenital adrenal hyperplasia?
What is the difference between classic and non-classic LCAH?
What does the two-hit hypothesis mean in STAR deficiency?
How can STAR deficiency affect a baby’s sex development?
How do karyotype, genetic testing, and imaging help explain my child’s anatomy?
Will a child with STAR deficiency need hormone replacement at puberty?
Can STAR deficiency affect ovarian function later?
Get notified when new evidence is published on Congenital lipoid adrenal hyperplasia due to STAR deficency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
The Steroidogenic Acute Regulatory (STAR) Gene Anatomy, Expression, and Roles.
Lim JH, Cheon YP
Development & reproduction 2025; (29(3)):63-80 doi:10.12717/DR.2025.29.3.63.
PMID: 41103362 - 2
Clinical spectrum of human STAR variants and their genotype-phenotype correlation.
Altinkilic EM, Augsburger P, Pandey AV, Flück CE
The Journal of endocrinology 2024; (262(3)).
PMID: 38913505 - 3
Disorders in the initial steps of steroid hormone synthesis.
Miller WL
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):18-37 doi:10.1016/j.jsbmb.2016.03.009.
PMID: 26960203 - 4
STAR/STARD1: A mitochondrial intermembrane space cholesterol shuttle degraded through mitophagy.
Koganti PP, Zhao AH, Kern MC, et al.
Proceedings of the National Academy of Sciences of the United States of America 2025; (122(41)):e2508809122 doi:10.1073/pnas.2508809122.
PMID: 41055982 - 5
In Vivo Verification of the Pathophysiology of Lipoid Congenital Adrenal Hyperplasia in the Adrenal Cortex.
Mizuno Y, Ishii T, Hasegawa T
Endocrinology 2019; (160(2)):331-338 doi:10.1210/en.2018-00777.
PMID: 30576426 - 6
Thirty years of StAR gazing. Expanding the universe of the steroidogenic acute regulatory protein.
Miller WL
The Journal of endocrinology 2025; (264(3)).
PMID: 39773408 - 7
Establishment of Star-edited Y1 cells as a novel in vitro functional assay for STAR.
Sato T, Narumi S, Sakuma T, et al.
Journal of molecular endocrinology 2024; (73(4)).
PMID: 39326452 - 8
Clinical and molecular characterization of thirty Chinese patients with congenital lipoid adrenal hyperplasia.
Zhang T, Ma X, Wang J, et al.
The Journal of steroid biochemistry and molecular biology 2021; (206()):105788 doi:10.1016/j.jsbmb.2020.105788.
PMID: 33227378 - 9
[Clinical and StAR genetic characteristics of 33 children with congenital lipoid adrenal hyperplasia].
Zheng WQ, Duan Y, Xiao B, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2022; (60(10)):1066-1071 doi:10.3760/cma.j.cn112140-20220322-00233.
PMID: 36207855 - 10
Clinical Features of 57 Patients with Lipoid Congenital Adrenal Hyperplasia: Criteria for Nonclassic Form Revisited.
Ishii T, Tajima T, Kashimada K, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(11)) doi:10.1210/clinem/dgaa557.
PMID: 32835366 - 11
A novel variant of the STAR gene: nonclassical presentation from Turkey.
Aytaç Kaplan EH, Gezdirici A, Kocabey Sütçü Z, Gökpinar İli E
Journal of pediatric endocrinology & metabolism : JPEM 2024; (37(9)):835-839 doi:10.1515/jpem-2024-0156.
PMID: 39042921 - 12
Disorders of Sex Development of Adrenal Origin.
Finkielstain GP, Vieites A, Bergadá I, Rey RA
Frontiers in endocrinology 2021; (12()):770782 doi:10.3389/fendo.2021.770782.
PMID: 34987475 - 13
Steroidogenic acute regulatory protein (STAR) deficiency: Our experience and systematic review for phenotype-genotype correlation.
Phadte A, Dhole C, Hegishte S, et al.
Clinical endocrinology 2024; (100(5)):431-440 doi:10.1111/cen.15032.
PMID: 38368602 - 14
Clinical characteristics of a male child with non-classic lipoid congenital adrenal hyperplasia and literature review.
Lu W, Zhang T, Zhang L, et al.
Frontiers in endocrinology 2022; (13()):947762 doi:10.3389/fendo.2022.947762.
PMID: 36407315 - 15
Pubertal and Adult Testicular Functions in Nonclassic Lipoid Congenital Adrenal Hyperplasia: A Case Series and Review.
Ishii T, Hori N, Amano N, et al.
Journal of the Endocrine Society 2019; (3(7)):1367-1374 doi:10.1210/js.2019-00086.
PMID: 31286101 - 16
A rare cause of primary adrenal insufficiency due to a homozygous Arg188Cys mutation in the STAR gene.
Burget L, Parera LA, Fernandez-Cancio M, et al.
Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-18-0003.
PMID: 29576868 - 17
Clinical Characteristics and Outcomes of Korean Patients with Lipoid Congenital Adrenal Hyperplasia: An Analysis of Data from the Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Disease (OUTSPREAD) Cohort Study.
Lee Y, Kim M, Lee YJ, et al.
Endocrinology and metabolism (Seoul, Korea) 2026; (41(4)):566-578 doi:10.3803/EnM.2025.2611.
PMID: 42190700 - 18
Pubertal Development and Pregnancy Outcomes in 46,XX Patients With Nonclassic Lipoid Congenital Adrenal Hyperplasia.
Hatabu N, Amano N, Mori J, et al.
The Journal of clinical endocrinology and metabolism 2019; (104(5)):1866-1870 doi:10.1210/jc.2018-01752.
PMID: 30476142 - 19
Gonadotropin-Releasing Hormone Analog Followed by Sex Hormone Therapy as a Preventive Strategy against Ovarian Complications in Congenital Lipoid Adrenal Hyperplasia: A Case Report.
Ishii T, Shindo J, Hashimoto N, et al.
Hormone research in paediatrics 2026; 1-8 doi:10.1159/000553134.
PMID: 42301958
This page is for informational purposes only and does not constitute medical advice. Your child’s pediatric endocrinology, genetics, and DSD care team should interpret STAR results and guide decisions about anatomy, puberty, and hormone therapy.